Novo Nordisk A/S reported a 19% increase in sales to DKK 78.1 billion for Q1 2025, with diabetes and obesity care sales growing by 21% and 67%, respectively. The company anticipates a sales growth outlook of 13-21% at constant exchange rates for 2025, citing challenges from compounded GLP-1s in the US.